Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease
Brian Bressler(University of British Columbia), Ernest G. Seidman(Université de Montréal), Remo Panaccione(University of Calgary), Richard N. Fedorak(University of Alberta)
Cited by 82
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k